OKYO Bathi resik saben saham (EPS TTM) OKYO Pharma Limited

OKYO Pharma Limited is gaining the trust of physicians by developing treatments for ophthalmological pain and dry eye syndrome. These innovations are based on the development of next-generation peptide inhibitors for corneal therapy. The company's EPS TTM trend underscores business stability within the safe havens of the US and UK, while -0.19 reflects the current net income per share.
Ringkesan rincian data analitis okyopharma.com (OKYO)

Net income per share (TTM) measures the actual business earnings attributable to a single share of capital over a year. By analyzing the rolling annual net income per share, an investor assesses profit generation efficiency without accounting for share dilution. This metric compares market value with the issuer's actual financial results. For OKYO Pharma Limited (OKYO), such calculations are critical, as geopolitical sanctions and raw material logistics disruptions directly limit drug production. This makes profit dynamics the primary indicator of the company's resilience to external shocks.